Geron stock reports USD 57.48 million Q2 revenue

Published on 09/30/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron stock posted a USD 16.68 million Q2 net loss on June 30, 2026. The consensus target is USD 4.00, while analysts rate the shares Hold.

GERN, US3741631036, Illustration mit AI erstellt.

Geron stock (ISIN US3741631036) reported USD 57.48 million in revenue for Q2 2026, while net income attributable to common shareholders was a loss of USD 16.68 million for the quarter ended June 30, 2026. The figures keep revenue growth and the path to profitability at the center of the investment case.

Revenue beats while losses persist

According to MarketBeat on September 29, 2026, Geron's Q2 earnings per share came in at a loss of USD 0.02, compared with a consensus loss of USD 0.01. Revenue of USD 57.48 million exceeded the USD 55.30 million consensus estimate, creating a clear split between commercial traction and earnings performance.

The reported Q2 revenue was USD 5.64 million above consensus, equal to 10.20 percent. The earnings shortfall was USD 0.01 per share, so the revenue beat did not translate into a narrower quarterly loss.

RYTELO supports the commercial case

Geron develops hematology medicines built around telomerase inhibition. Its lead product, RYTELO, is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes, while imetelstat is also being studied in myelofibrosis.

Geron's investor-relations page identifies Q2 2026 as the company's latest earnings period and lists the September 18, 2026 inducement-grant release. In that release, Geron Corporation said it granted options covering 821,250 shares to nine newly hired employees, with an exercise price of USD 1.32 per share.

Hold consensus sets the benchmark

MarketBeat reported a consensus rating of Hold and a consensus price target of USD 4.00 on September 29, 2026. The target stands USD 2.76 above the USD 1.24 primary-market reference used in the same market context, but the latest quarter's loss shows why revenue expansion and cash discipline remain important indicators.

Market value stays below USD 800 million

Geron had a market capitalization of USD 795.5 million as of September 29, 2026. Its 52-week range was USD 1.04 to USD 2.01, placing the reported USD 1.24 quote USD 0.20 above the yearly low and USD 0.77 below the yearly high.